Advertisement

Biogerontology

, Volume 3, Issue 1–2, pp 19–24 | Cite as

Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling

  • Miranda D. Grounds
Article

Abstract

This paper examines two major possibilities for the striking loss of skeletal muscle mass and strength that occurs in very old animals and humans. It is concluded that muscle regeneration is not significantly impaired with age. Instead, it seems that individual myofibres undergo atrophy, with selective death of the fast type 2B myofibres, due to the combined effects of many age-related changes the main causes being: nutrition(under-nutrition and lack of vitamin D),decreased hormone levels (e.g growth hormone, testosterone), reduced physical activity, and a loss of nerves that innervate the muscles. The discussion focusses on the central role of a local muscle form of insulin-like growth factor-I (IGF-I) in muscle hypertrophy, atrophy and motor neurone loss. Reduced IGF-Isignalling is involved in muscle atrophy and results from decreased muscle exercise, reduced growth hormone and insulin levels, reduced vitamin D, and treatment with drugs like corticosteroids, dexamethasone, and cyclosporin. In addition, elevated levels of inflammatory cytokines like TNF-α and IL-6can cause muscle wasting (cachexia) although this is usually associated with disease, andTNF-α may also act (at least in part) by inhibiting IGF-I signalling. The possible clinical prevention of age-related muscle wasting (and associated motor neurone loss) by the locally acting muscle isoform of IGF-I is discussed.

ageing atrophy denervation hypertrophy IGF-1 motorneurone death regeneration skeletal muscle 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Argiles JM, Alvarez B, Carbo N, Busquets S, Van Royen M and Lopez-Soriano FJ (2000) The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting. Eur Cytokine Netw 11: 552-559PubMedGoogle Scholar
  2. Argiles JM, Meijsing SH, Pallares-Trujillo J, Guirao X and Lopez-Soriano FJ (2001) Cancer cachexia: a therapeutic approach. Med Res Rev 21: 83-101PubMedCrossRefGoogle Scholar
  3. Balaivas M and Carlson BM (1991) Muscle fibre branching: differences between grafts in young and old rats. Mech Ageing Dev 60: 43-53CrossRefGoogle Scholar
  4. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N and Sweeney HL (1998) Viral mediated expression of insulin-like growth factor I blocks the age-related loss of skeletal muscle function. Proc Natl Acad Sci USA 95: 15603-15607PubMedCrossRefGoogle Scholar
  5. Barton-Davis ER, Shoturma DI and Sweeney HL (1999) Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol Scand 167: 301-305PubMedCrossRefGoogle Scholar
  6. Baumgartner RN, Waters DL, Gallagher D, Morley JE and Garry PJ (1999) Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 107: 123-136PubMedCrossRefGoogle Scholar
  7. Beiner JM, Jokl P, Cholewicki J and Panjabi MM (1999) The effect of anabolic steroids and corticosteroids on healing of muscle contusion injury. Am J Sports Med 27: 2-9PubMedGoogle Scholar
  8. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, Silani V, Vos PE, Wokke JHJ and Dobbins T (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Eur ALS Neurol 51: 583-586Google Scholar
  9. Brooks SV and Faulkner JA (1996) The magnitude of the initial injury induced by stretches of maximally activated muscle fibers of mice and rats increases with old age. J Physiol 497: 573-580PubMedGoogle Scholar
  10. Broussard SR, Zhou J, Venters HD, Bluthe RM, Freund GG, Johnson RS, Dantzer R and Kelley KW(2001) At the interface of environmental-immune interactions: cytokine and growth factor receptors. J Anim Sci 79 (E Suppl): E268-E284Google Scholar
  11. Buitrago C, Vazquez G, De Boland AR and Boland RL (2000) Activation of Src kinase in skeletal muscle cells by 1,1,25-(OH(2))-vitaminD(3) correlates with tyrosine phosphorylation of the vitamin D receptor (VDR) and VDR-Src interaction. J Cell Biochem 79(2): 274-281PubMedCrossRefGoogle Scholar
  12. Carlson BM, Dedkov EI, Borisov AB and Faulkner JA (2001) Skeletal muscle regeneration in very old rats. J Gerontol 56A: B1-B10Google Scholar
  13. Carlson BM and Faulkner JA (1998) Muscle regeneration in young and old rats: effects of motor nerve transection with and without marcaine treatment. J Gerontol 53: B52-57Google Scholar
  14. Chapman IM, MacIntosh CG, Morley JE and Horowitz M (2002) The anorexia of ageing. Biogerontology 3: 67-71 (this issue) Cleveland DW (1999) From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS. Neuron 24: 515-520Google Scholar
  15. Devor ST and Faulkner JA (1999) Regeneration of new fibres in muscles of old rats reduces contraction-induced injury. J Appl Physiol 87: 750-756PubMedGoogle Scholar
  16. Eriksen EF and Glerup H (2002) Vitamin D deficiency and aging: implications for general health and osteoporosis. Biogerontology 3: 73-77 (this issue)PubMedCrossRefGoogle Scholar
  17. Faulkner JA, Brooks SV and Zerba E (1995) Muscle atrophy and weakness with aging: contraction-induced injury as an underlying mechanism. J Gerontol 50A: 124-129Google Scholar
  18. Festoff BW, Yang SX, Vaught J, Bryan C and Ma JY (1995) The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. J Neurol Sci 129 (Suppl): 114-121PubMedCrossRefGoogle Scholar
  19. Frost RA, Lang CH and Gelato MC (1997) Transient exposure of human myoblasts to tumour necrosis factor-? inhibits serum and insulin-like growth factor-I stimulated protein synthesis. Endocrinology 138: 4153-4159PubMedCrossRefGoogle Scholar
  20. Gayan-Ramirez G, Vanderhoydonc F, Verhoeven G and Decramer M (1999) Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Critical Care Med 159: 283-289Google Scholar
  21. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S and Bhasin S (1998) Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proce Natl Acad Sci USA 95: 14938-14943CrossRefGoogle Scholar
  22. Grounds MD (1991) Towards understanding skeletal muscle regeneration. Pathol Res Practice 187: 1-22Google Scholar
  23. Grounds MD (1998) Age-Associated changes in the response of skeletal muscle cells to exercise and regeneration. Ann NY Acad Sci 854: 78-91PubMedCrossRefGoogle Scholar
  24. Hantai D, Akaaboune M, Lagord C, Murawsky M, Houenou LJ, Festoff BW, Vaught JL, Rieger F and Blondet B (1995) Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease. J Neurol Sci 129(Suppl): 122-126PubMedCrossRefGoogle Scholar
  25. Hayes A. and Williams DA (1998) Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: 1. Clenbuterol. J Neurol Sci 157: 122-128PubMedCrossRefGoogle Scholar
  26. Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE and Vaught JL (1993) Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 124: 73-88PubMedCrossRefGoogle Scholar
  27. Luff AR (1998) Age-associated changes in the innervation of muscle fibres and changes in the mechanical properties of motor units. Ann NY Acad Sci 854: 92-101PubMedCrossRefGoogle Scholar
  28. McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B and Goldspink G (1999) Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol 15: 583-592CrossRefGoogle Scholar
  29. McPherron AC, Lawler AM and Lee S-J (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83-90PubMedCrossRefGoogle Scholar
  30. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ and Alexander WS (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405: 1069-1073PubMedCrossRefGoogle Scholar
  31. Miller RG (1999) Clinical trials in motorneuron disease. J Child Neurol 14: 173-179PubMedGoogle Scholar
  32. Musaro A, McCullagh K, Houghton J, Elizabeth R, Barton H, Sweeney L and Rosenthal N (2001) < Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genet 27: 195-200PubMedCrossRefGoogle Scholar
  33. Musaro A, McCullagh KJA, Naya FJ, Olson EN and Rosenthal N (1999) IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400: 581-585PubMedCrossRefGoogle Scholar
  34. Petersen JE, Kulik G, Jelinek T, Reuter CW, Shannon JA and Weber MJ (1996) Src phorphorylates the insulin-like growth factor type I receptor on the autophosporylation sites. requirement for transformation by src. J Biol Chem 271: 31562-31571CrossRefGoogle Scholar
  35. Ravaglia G, Forti P, Maioli F, Nesi B, Pratelli L, Cucinotta D, Bastagli L and Cavelli G (2000) Body composition, Sex steroids, IGF-I, and bone-mineral status in aging men. J Gerontol Med Sci 55A: M516-M521Google Scholar
  36. Rosenblatt JD and Parry DJ (1992) Gamma-Irradiation Prevents Compensatory Hypertrophy of Overloaded Mouse Extensor Digitorum Longus Muscle. J Appl Physiol 73: 2538-2543PubMedGoogle Scholar
  37. Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV, Fowke PJ and Bass JJ (1999) Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 180: 1-9PubMedCrossRefGoogle Scholar
  38. Singleton JR, Baker BL and Thorburn A (2000) Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 141: 2945-2950PubMedCrossRefGoogle Scholar
  39. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO and Ohlsson C (1999) Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96: 7088-7092PubMedCrossRefGoogle Scholar
  40. Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF and Weinberg RA (1999) Interaction of the Ski Oncoprotein with Smad3 regulates TGF-? signalling. Mol Cell 4: 499-509PubMedCrossRefGoogle Scholar
  41. Tawa NEJ and Goldberg AL (1994) Protein and Amino Acid Metabolism in Muscle. In: Engel AG and Franzini-Armstrong G (eds) Myology (2nd Edition), Vol 1, pp 683-707. McGraw Hill, New YorkGoogle Scholar
  42. Vandenburgh H, Chromiak J, Shansky J, Del Tatto M and Lemaire J (1999) Space travel directly induces skeletal muscle atrophy. FASEB J 13: 1031-1038PubMedGoogle Scholar
  43. Vergani L, Losa M, Lesma E, Di Giulio AM, Torsello A, Muller EE and Gorio A (1999) Glycosaminoglycans boost insulin-like growth factor-I-promoted neuroprotection: blockade of motor neuron death in the wobbler mouse. Neuroscience 93: 565-572PubMedCrossRefGoogle Scholar
  44. Verhaar HJ, Samson MM, Jansen PA, de Vreede PL, Manten JW and Duursma SA (2000) Muscle strength, functional mobility and vitamin D in older women. Aging 12: 455-460PubMedGoogle Scholar
  45. Wolkow CA, Kimura KD, Lee M-S and Ruvkun G (2000) Regulation of C. elegans life-span by insulinlike signaling in the nervous system. Science 290: 147-150PubMedCrossRefGoogle Scholar
  46. Zhu X, Hadhazy M, Wehling M, Tidball JG and McNally EM(2000) Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 474: 71-75PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Miranda D. Grounds
    • 1
  1. 1.Department of Anatomy and Human BiologyThe University of Western AustraliaCrawleyAustralia

Personalised recommendations